The arsenal of tools available for drug discovery has significantly expanded, with advancements in genetics, multi-omics, and single-cell sequencing dramatically transforming the quantity of data that can be obtained from minimal human samples. These developments enable a deeper understanding of the pathogenesis of metabolic diseases, as well as the mechanisms of action and treatment responses for specific therapies targeting obesity, T2D (Type 2 Diabetes), and MASH (Metabolic Associated Steatohepatitis). Additionally, advancements in non-invasive tools, such as enhanced in vivo imaging with and without tracers, have improved our ability to diagnose and monitor treatment responses effectively.

This Forum will focus on how data generated through cutting-edge tools (such as genetics, proteomics, metabolomics, transcriptomics, single-cell spatial metabolomics, and single-cell nuclei transcriptomics, along with in vivo imaging) are revolutionising our understanding of disease progression, diagnosis, and treatment efficacy. In addition, the Forum will discuss the identification of novel obesity targets through genetic analysis and provide insights into the mode of action of a new drug modality.

Innovative tools are steering the future of drug discovery. So, buckle up and join us in Copenhagen to explore these exciting developments.